The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-β-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.

Disclosed herein are methods for treating cancer by administering to a subject a composition comprising a bacteriophage expressing a fragment of human aspartate -hydroxylase (ASPH) and an immune checkpoint protein inhibitor.

An automated method of evaluating a collected fluid sample includes: filling a sample cavity with the collected fluid sample; adding a buffer solution; separating the collected fluid sample into a first portion and a second portion; mixing the second portion with tagged antibodies; removing leftover tagged antibodies; and measuring a difference between the first portion and the second portion. A sample collection and testing device includes: a reference cavity comprising a reference fluid sample; a test cavity comprising a test fluid sample; a reference measurement element associated with the reference cavity; and a test measurement element associated with the test cavity. A method of evaluating a collected fluid sample including: separating the sample; pumping a first portion to a first measurement cavity; adding a solution to a second portion and pumping the mixture to a second measurement cavity; and measuring a charge difference between the first and second measurement cavities.

The present invention provides a peptide-based immunotherapy for ASPH-expressing tumors.

The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]. beta.-hydroxylase (HAAH). The present invention contemplates bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.

Provided herein are polypeptide epitopes of aspartyl-(asparaginyl)-3-hydroxylase (AABH) as well as polyepitopes thereof. Also provided are antibodies that specifically bind these polypeptide epitopes and poly epitopes, as well as binding the aspartyl-(asparaginyl)-3-hydroxylase protein itself. The disclosure further provides methods of assaying for AABH polypeptide epitopes, cells expressing these polypeptide epitopes and the AABH protein. Also provided are methods of diagnosing cancer by the detection of AABH peptides and methods of treating cancer by targeting cells that express AABH.

Provided herein are anti-ASPH chimeric antigen receptors (CARs), genetically modified immune effector cells, and use of these compositions to effectively treat ASPH expressing cancers.

An automated method of evaluating a collected fluid sample includes: filling a sample cavity with the collected fluid sample; adding a buffer solution; separating the collected fluid sample into a first portion and a second portion; mixing the second portion with tagged antibodies; removing leftover tagged antibodies; and measuring a difference between the first portion and the second portion. A sample collection and testing device includes: a reference cavity comprising a reference fluid sample; a test cavity comprising a test fluid sample; a reference measurement element associated with the reference cavity; and a test measurement element associated with the test cavity. A method of evaluating a collected fluid sample including: separating the sample; pumping a first portion to a first measurement cavity; adding a solution to a second portion and pumping the mixture to a second measurement cavity; and measuring a charge difference between the first and second measurement cavities.

The present invention encompasses a cancer vaccine therapy targeting Aspartyl-[Asparaginyl]-,8-hydroxylase (HAAH). The present invention contemplate bacteriophage expressing HAAH peptide fragments and methods for using said bacteriophage in methods of treating cancer.